NVIV
InVivo Therapeutics Holdings Corporation
Set alert
52-week range unavailable
- Open
- 0.4081
- Prev close
- 0.3207
- Mkt cap
- 995.92K
- Vol
- 1.61M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.301
- High
- 0.409
- Forward P/E
- -0.03
- Beta
- 0.66
- Short ratio
- 0.91
- Inst. own
- 3.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2024
- 50-d avg
- 0.605553
- 200-d avg
- 0.98865
- 1y target
- 0.00
Key statistics
- Market cap
- 995.92K
- Enterprise value
- -7.59M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.11
- EPS (TTM)
- -3.28
- Beta
- 0.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.03M
- Total cash
- 8.58M
- Total debt
- 0
- Return on equity
- -98.11%
- Shares outstanding
- 3.11M
- Short % of float
- 0.64%
- 50-day average
- 0.605553
- 200-day average
- 0.98865
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 14, 2024
Expected Feb 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 2, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
About InVivo Therapeutics Holdings Corporation
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- invivotherapeutics.com
News
- Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?
- Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Stocks That Hit 52-Week Lows On Monday
- Why Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
- US Stocks Turn Lower; S&P 500 Down 1%
- Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Your note
Sign in to keep a note on NVIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHRISTOPHER RICHARD C | Chief Financial Officer | Purchase | Mar 9, 2020 | 5,220 |
| FOOSE BRICE | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 5, 2023 | 0 |
| JOSEPH TAMARA L | General Counsel | Stock Award(Grant) | Dec 30, 2015 | 17,027 |
| LORIANNE MASUOKA K | Officer | Stock Award(Grant) | Dec 30, 2015 | 265 |
| MCALLISTER STEVEN F | Chief Financial Officer | Stock Award(Grant) | Dec 30, 2015 | 19,160 |
| MERRIFIELD C ANN | Director | Purchase | Mar 9, 2020 | 3,639 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.12% | 34,714 | 46.86K | Jun 29, 2023 |
| Vanguard Group Inc | 0.85% | 26,246 | 35.43K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.56% | 17,266 | 23.31K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.36% | 11,169 | 15.08K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.24% | 7,391 | 9.98K | Jun 29, 2023 |
| Morgan Stanley | 0.01% | 270 | 364 | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.85% | 26,246 | 35.43K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.22% | 6,721 | 8.80K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.08% | 2,425 | 3.18K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 1,757 | 2.30K | May 30, 2023 |